Disease & disorder

uveitis

MONDO:0020283

An inflammatory process affecting a part of or the entire uvea. Causes include inflammatory agents (e.g., herpes simplex, herpes zoster, leptospirosis) and systemic diseases (e.g., inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis). Patients present with pain and redness in the eye, light sensitivity, and blurred and decreased vision.

Clinical trials21
Recruiting0
Drug concepts studied2
Synonyms4

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Uveitis

Uveitis () is inflammation of the uvea, the pigmented layer of the eye between the inner retina and the outer fibrous layer composed of the sclera and cornea. The uvea consists of the middle layer of pigmented vascular structures of the eye and includes the iris, ciliary body, and choroid. Uveitis is described anatomically, by the part of the eye affected, as anterior, intermediate, or posterior, or panuveitic if all parts are involved. Anterior uveitis (iridocyclitis) is the most common, with the incidence of uveitis overall affecting approximately 1:4500, most commonly those between the ages of 20 and 60. Symptoms include eye pain, eye redness, floaters, and blurred vision, and ophthalmic examination may show dilated ciliary blood vessels and the presence of cells in the anterior chamber. Uveitis may arise spontaneously, have a genetic component, or be associated with an autoimmune disease or infection. While the eye is a relatively protected environment, its immune mechanisms may be activated, resulting in inflammation and tissue destruction associated with T-cell activation. Uveitis is an ophthalmic emergency that requires urgent control of the inflammation to prevent vision loss. Treatment typically involves the use of topical eye drops (steroids), intravitreal injection, newer biologics, and treating any underlying disease. While initial treatment is usually successful, complications include other ocular disorders, such as uveitic glaucoma, retinal detachment, optic nerve damage, cataracts, and in some cases, a permanent loss of vision. In the United States, uveiti...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

21 shown
Wide Field OCTA in Ocular DiseasesNCT07298174 · 2026-01-01
NOT_YET_RECRUITING
High Resolution Optical Coherence TomographyNCT05130385 · 2021-11-30
UNKNOWN
Biomarkers of Common Eye DiseasesNCT04101604 · 2019-09-26
UNKNOWN
Feasibility Study and Preliminary Application Study on Iris OCTANCT03631108 · 2018-10-01
UNKNOWN
Chronic Inflammatory Disease, Lifestyle and Treatment ResponseNCT03173144 · 2017-09-21
COMPLETED
LSFG-SKIN, Laser Speckle FlowgraphyNCT03660618 · 2017-05-23
TERMINATED
Factors Affecting Aqueous Humor Outflow Facility in Patients with UveitisNCT02613442 · 2017-04-13
WITHDRAWN
Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin HospitalNCT02998398 · 2015-10-01
COMPLETED
Phenomics in Autoimmune and Inflammatory DiseasesNCT02466217 · 2015-07-29
COMPLETED
Assessment of Retinal Nerve Fibre Layer by Optical Coherence Tomography in Uveitis Patients With PapilloedemaNCT01170481 · 2009-07-01
COMPLETED
Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot StudyNCT00855608 · 2009-03-01
UNKNOWN
Genetics and Markers of Degenerative and Inflammatory Eye DiseasesNCT00647439 · 2008-03-27
COMPLETED
Daclizumab Injections to Treat Non-Infectious Sight-Threatening UveitisNCT00043667 · 2002-08-01
COMPLETED
Differences in Genes and Proteins in Active and Controlled UveitisNCT00357266 · 2002-02-01
COMPLETED
HAT in Eye Complications of Behcet's DiseaseNCT00001865 · 1999-07-01
COMPLETED
TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid ArthritisNCT00001862 · 1999-02-01
COMPLETED
The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid ArthritisNCT00001614 · 1997-07-01
COMPLETED
ANTI-TAC THERAPY FOR UVEITISNCT00001526 · 1996-06-04
COMPLETED
Spontaneous Coronary Artery Dissection (SCAD) and AutoimmunityNCT03941184 · 1995-01-01
COMPLETED
Tissue Studies of Human Eye DiseasesNCT00001310 · 1992-03-05
TERMINATED
The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid ArthritisNCT00012506
UNKNOWN

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.